<DOC>
	<DOCNO>NCT02145234</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , immunogenicity , pharmacokinetics pharmacodynamics single multiple dos BMS-986089 healthy adult subject .</brief_summary>
	<brief_title>Placebo-Controlled , Single Multiple Ascending Subcutaneous Dose Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics BMS-986089 Healthy Adult Subjects</brief_title>
	<detailed_description>Primary Purpose - : Protocol design assess safety , tolerability , immunogenicity , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) BMS-986089 healthy subject Enrollment : Single ascend dose panel : 48 subject , Multiple ascend dose panel : 96 Minimum age : 18 year ( Elderly MAD Panel 65 year age ) Maximum age : 55 year ( Elderly MAD Panel 70 year age )</detailed_description>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs clinical laboratory determination Men woman childbearing potential ( ie , postmenopausal Surgically sterile WOCBP ) age 21 55 year Women must breastfeed Men sexually active woman child bear potential ( WOCBP ) must use contraceptive method failure rate le 1 % per year Any significant acute chronic medical illness Any major surgery within 6 week study drug administration Any condition clearly require medical surgical treatment period study participation Any bone trauma bone surgery within 3 month study drug administration Known suspect autoimmune disorder Donation blood plasma blood bank clinical study ( except screen visit ) within 6 week study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>